Journal article
Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial.
- Kraler S Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
- Wenzl FA Department of Cardiology, German Heart Centre Munich, Technical University of Munich, Munich, Germany.
- Lüscher TF Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
- 2020-10-22
Published in:
- European journal of clinical investigation. - 2020
English
Over the last decades, our understanding of inflammatory processes involved in atherogenesis advanced considerably, with elements of R. Virchow's concept on atherosclerosis as a chronic inflammation induced by cholesterol appearing highly topical. Indeed, the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) taught us that specifically targeted anti-inflammatory therapy can confer protection from recurrent cardiovascular (CV) events without affecting lipid levels.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1111/eci.13424
- PMID 33091147
- Persistent URL
- https://sonar.rero.ch/global/documents/164378
Statistics
Document views: 14
File downloads: